Mielóma multiplex: vizsgálatok itt: Dél-Korea

In Dél-Korea 36 Also abroad 704

36 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.

1. fázisTaking people
A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Gangnam-Gu
Életkor
18 év and over
People
160 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07558915
3. fázisTaking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Busan, Hwasun, Incheon, Jeonju, Seoul
Életkor
18 év and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
1/2. fázisTaking people
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Where
Seoul
Életkor
18 év and over
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05583617 · EU 2023-504484-16-00
1. fázisTaking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Where
Seocho, Seoul
Életkor
18 év and over
People
120 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT05927571 · EU 2023-504657-13-00
3. fázisTaking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Hwasun, Seoul, Ulsan
Életkor
18 év and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
3. fázisTaking people
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Where
Hwasun, Seoul, Suwon
Életkor
18 év and over
People
270 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00
2. fázisTaking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Jeollanam-do, Seoul
Életkor
18 év and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
3. fázisTaking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Busan, Daegu, Goyang-si, Hwasun, Incheon, Seoul
Életkor
18 év and over
People
1590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
3. fázisTaking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Gyeonggi-do, Jeollanam-do, Seoul, Ulsan
Életkor
18 év and over
People
1000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
3. fázisTaking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Busan, Hwasun, Seongnam, Seoul
Életkor
18 év and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
3. fázisTaking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Seoul
Életkor
18 év and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
3. fázisTaking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Hwasun-gun, Seongnam, Seoul
Életkor
18 év and over
People
1060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
1/2. fázisTaking people
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Where
Goyang, Seoul
Életkor
18 év and over
People
387 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00
1/2. fázisTaking people
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
GangnamGu, SeochoGu, SeodaemunGu, Seoul, SongpaGu
Életkor
18 év and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00
3. fázisTaking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Seoul
Életkor
18 év to 130 év
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
1. fázisTaking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Seoul
Életkor
18 év and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
2. fázisCsak meghívásos
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Seoul
Életkor
18 év and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
1/2. fázisTaking people
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Where
Seoul
Életkor
18 év and over
People
258 worldwide
Run by
Sanofi
See details and how to joinNCT04643002
3. fázisTaking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
Jeollanam-do, Seoul
Életkor
18 év and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
3. fázisTaking people
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Where
Gwangju, Seoul
Életkor
18 év and over
People
1594 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00
No phaseTaking people
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
Where
Hwasun, Seoul
Életkor
18 év and over
People
15
Run by
Bristol-Myers Squibb
See details and how to joinNCT06698887
3. fázisTaking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Seoul
Életkor
18 év and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
2. fázisTaking people
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Where
Seoul
Életkor
18 év and over
People
210 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00
3. fázisTaking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Goyang-si, Gyeonggi-do, Hwasun, Seoul
Életkor
18 év and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
2. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Where
Seoul, Ulsan
Életkor
18 év and over
People
200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00